Novo Nordisk to test diabetes tablet against Eli Lilly drug
A clinical trial will compare the effect of Novo Nordisk’s semaglutide with Eli Lilly’s Jardiance on patients’ blood sugar levels and body weight.
by christian bundgaard, translated by daniel pedersen
In a new clinical study, Novo Nordisk is seeking to measure the efficacy and safety of a once-daily tablet version of semaglutide, comparing the drug to Eli Lilly’s daily tablet treatment, empagliflozin, according to a filing on database Clinical Trials.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg)
.jpg&w=384&q=75)
